AKESO(HK:09926) Zhi Tong Cai Jing·2025-09-01 09:33Core Viewpoint - The report from Credit Lyonnais raises the target price for Kangfang Biotech (09926) from HKD 112.6 to HKD 177, maintaining an outperform rating, indicating strong confidence in the company's future performance [1] Sales and Profit Forecast - The company is expected to achieve a year-on-year sales growth of 33.7% in the first half of 2025, which aligns with market expectations [1] - Sales forecasts for Kangfang Biotech for 2025 to 2027 have been adjusted upwards by 1.2%, 5.1%, and 18.9% respectively [1] - Net profit forecasts for the fiscal years 2026 and 2027 have been increased by 10.9% and 35% respectively [1] Clinical Trial Results - The analysis results for AK112's overall survival (OS) are statistically significant and clinically meaningful, providing positive insights for the overseas HARMONi trial [1]